epiHERA™

epiHERA™ is a Minimally Invasive Early Endometrial Cancer Detection Test

Endometrial Cancer is the most commonly diagnosed gynecologic cancer. An estimated 417,367 people were diagnosed with endometrial cancer in 2020.1

[1] https://www.cancer.net/cancer-types/uterine-cancer/statistics

INEX's Solution

epiHERA™ is a minimally invasive early endometrial cancer detection test that identifies methylated biomarkers which give indications of gene repression from malignancy.

MINIMALLY INVASIVE

Use of simple cervical swab instead of processes like Dilatation & Curettage thus decreasing pain & discomfort.

EASE OF OPERATIONS

Sample collection can be performed in clinics without surgical setup. Fast turnaround time for results from molecular lab instead of a histopathology lab.

EASE OF ADOPTION

Tests can be implemented and performed with simple qPCR lab setup.

INTERESTED?

If you're interested in epiHERA™ and would like to know more or partner with us, let's chat.